FHIT and p53 status and response to platinum-based treatment in advanced non-small cell lung cancer

Current Cancer Drug Targets

Volumn 8, Issue 5, 2008, Pages 342-348

  Cortinovis, D L ^a   Andriani, F ^a   Livio, A ^a   Fabbri, A ^a   Perrone, F ^a   Marcomini, B ^a   Pilotti, S ^a   Mariani, L ^a   Bidoli, P ^a   Bajetta, E ^a   Roz, L ^a   Sozzi, G ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Chemotherapy; FHIT; Lung cancer; p53

Indexed keywords

CARBOPLATIN; FRAGILE HISTIDINE TRIAD PROTEIN; GEMCITABINE; PLATINUM DERIVATIVE; PROTEIN P53;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; BLOOD TOXICITY; CANCER SURVIVAL; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; ESOPHAGITIS; FEMALE; FLU LIKE SYNDROME; GENE INACTIVATION; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; INFECTION; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PROGNOSIS; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUMOR BIOPSY; VOMITING;

ACID ANHYDRIDE HYDROLASES; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; DEOXYCYTIDINE; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM PROTEINS; NEOPLASM STAGING; POLYMERASE CHAIN REACTION; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 48849105881     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/156800908785133204     Document Type: Article

References (33)

1. Schiller, J. H.; Harrington, D.; Belani, C. P.; Langer, C.; Sandler, A.; Krook, J.; Zhu, J.; Johnson, D. H. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N. Engl. J. Med. 2002, 346, 92-98.
2. Fossella, F.; Pereira, J. R.; von Pawel, J.; Pluzanska, A.; Gorbounova, V.; Kaukel, E.; Mattson, K. V.; Ramlau, R.; Szczesna, A.; Fidias, P.; Millward, M.; Belani, C. P. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J. Clin. Oncol. 2003, 21, 3016-3024.
3. Gridelli, C.; Gallo, C.; Shepherd, F. A.; Illiano, A.; Piantedosi, F.; Robbiati, S. F.; Manzione, L.; Barbera, S.; Frontini, L.; Veltri, E.; Findlay, B.; Cigolari, S.; Myers, R.; Ianniello, G. P.; Gebbia, V.; Gasparini, G.; Fava, S.; Hirsh, V.; Bezjak, A.; Seymour, L.; Perrone, F. Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: a phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 2003, 21, 3025-3034.
4. Osada, H.; Takahashi, T. Genetic alterations of multiple tumor suppressors and oncogenes in the carcinogenesis and progression of lung cancer. Oncogene 2002, 21, 7421-7434.
5. Olaussen, K. A.; Dunant, A.; Fouret, P.; Brambilla, E.; Andre, F.; Haddad, V.; Taranchon, E.; Filipits, M.; Pirker, R.; Popper, H. H.; Stahel, R; Sabatier, L.; Pignon, J. P.; Tursz, T.; Le Chevalier, T.; Soria, J. C. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N. Engl. J. Med. 2006, 355, 983-991.
6. Lord, R. V.; Brabender, J.; Gandara, D.; Alberola, V.; Camps, C.; Domine, M.; Cardenal, F.; Sanchez, J. M.; Gumerlock, P. H.; Taron, M.; Sanchez, J. J.; Danenberg, K. D.; Danenberg, P. V.; Rosell, R. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin. Cancer Res. 2002, 8, 2286-2291.
7. Bepler, G.; Kusmartseva, I.; Sharma, S.; Gautam, A.; Cantor, A.; Sharma, A.; Simon, G. RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer. J. Clin. Oncol. 2006, 24, 4731-4737.
8. Levine, A. J. p53, the cellular gatekeeper for growth and division. Cell 1997, 88, 323-331.
9. Sozzi, G.; Veronese, M. L.; Negrini, M.; Baffa, R.; Cotticelli, M. G.; Inoue, H.; Tornielli, S.; Pilotti, S.; De Gregorio, L.; Pastorino, U.; Pierotti, M. A.; Ohta, M.; Huebner, K.; Croce, C. M. The FHIT gene 3p14.2 is abnormal in lung cancer. Cell 1996, 85, 17-26.
10. Roz, L.; Andriani, F.; Ferreira, C. G.; Giaccone, G.; Sozzi, G. The apoptotic pathway triggered by the Fhit protein in lung cancer cell lines is not affected by Bcl-2 or Bcl-x(L) overexpression. Oncogene 2004, 23, 9102-9110.
11. Andriani, F.; Perego, P.; Carenini, N.; Sozzi, G.; Roz, L. Increased Sensitivity to Cisplatin in Non-Small Cell Lung Cancer Cell Lines after FHIT Gene Transfer. Neoplasia 2006, 8, 9-17.
12. Bajetta, E.; Stani, S. C.; De Candis, D.; Zaffaroni, N.; Zilembo, N.; Cortinovis, D.; Aglione, S.; Mariani, L.; Formisano, B.; Bidoli, P. Preclinical and clinical evaluation of four gemcitabine plus carboplatin schedules as front-line treatment for stage IV non-small-cell lung cancer. Ann. Oncol. 2003, 14, 242-247.
13. Bidoli, P.; Zilembo, N.; Cortinovis, D.; Mariani, L.; Isa, L.; Aitini, E.; Cullurà, D.; Pari, F.; Nova, P.; Mancin, M.; Formisano, B.; Bajetta, E. Randomized phase II three-arm trial with three platinum-based doublets in metastatic non-small-cell lung cancer. An Italian Trials in Medical Oncology study. Ann. Oncol. 2007, 18, 461-467.
14. Sozzi, G.; Pastorino, U.; Moiraghi, L.; Tagliabue, E.; Pezzella, F.; Ghirelli, C.; Tornielli, S.; Sard, L.; Huebner, K.; Pierotti, M. A.; Croce, C. M.; Pilotti, S. Loss of FHIT function in lung cancer and preinvasive bronchial lesions. Cancer Res. 1998, 58, 5032-5037.
15. Perrone, F.; Oggionni, M.; Birindelli, S.; Suardi, S.; Tabano, S.; Romano, R.; Moiraghi, M. L.; Bimbi, G.; Quattrone, P.; Cantù, G.; Pierotti, M. A.; Licitra, L.; Pilotti, S. TP53, p14ARF, p16INK4a and H-ras gene molecular analysis in intestinal-type adenocarcinoma of the nasal cavity and paranasal sinuses. Int. J. Cancer 2003, 105, 196-203.
16. Ferretti, G.; Curigliano, G.; Pastorino, U.; Cittadini, A.; Flamini, G.; Calabro, M. G.; De Pas, T.; Orlando, L.; Mandala, M.; Colleoni, M.; Spaggiari, L.; Granone, P. L.; Pagliari, G.; De Braud, F.; Fazio, N.; Goldhirsch, A. Detection by denaturant gradient gel electrophoresis of tumor-specific mutations in biopsies and relative bronchoalveolar lavage fluid from resectable non-small cell lung cancer. Clin. Cancer Res. 2000, 6, 2393-2400.
17. Licitra, L.; Perrone, F.; Bossi, P.; Suardi, S.; Mariani, L.; Artusi, R.; Oggionni, M.; Rossini, C.; Cantù, G.; Squadrelli, M.; Quattrone, P.; Locati, L. D.; Bergamini, C.; Olmi, P.; Pierotti M. A.; Pilotti, S. High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma. J. Clin. Oncol. 2006, 24, 5630-5636.
18. Leong, S. S.; Rocha Lima, C. M.; Sherman, C. A.; Green, M. R. The 1997 International Staging System for non-small cell lung cancer: have all the issues been addressed? Chest 1999, 115, 242-248.
19. World Health Organization. WHO handbook for reporting results of cancer treatment. WHO offset publication No. 48. Geneva, Switzerland, 1979.
20. Andriani, F.; Conte, D.; Mastrangelo, T.; Leon, M.; Ratcliffe, C.; Roz, L.; Pelosi, G.; Goldstraw, P.; Sozzi, G.; Pastorino, U. Detecting lung cancer in plasma with the use of multiple genetic markers. Int. J. Cancer 2004, 108, 91-96.
21. Iliopoulos, D.; Guler, G.; Han, S. Y.; Johnston, D.; Druck, T.; McCorkell, K. A.; Palazzo, J.; McCue, P. A.; Baffa, R.; Huebner, K. Fragile genes as biomarkers: epigenetic control of WWOX and FHIT in lung, breast and bladder cancer. Oncogene 2005, 24, 1625-1633.
22. Ishii, H.; Dumon, K. R.; Vecchione, A.; Fong, L. Y.; Baffa, R.; Heubner, K.; Croce, C. M. Potential cancer therapy with the fragile histidine triad gene: review of the preclinical studies JAMA 2001, 21, 2441-2449.
23. Sozzi, G.; Tornielli, S.; Tagliabue, E.; Sard, L.; Pezzella, F.; Pastorino, U.; Minoletti, F.; Pilotti, S.; Ratcliffe, C.; Veronese, M. L.; Goldstraw, P.; Heubner, K.; Croce, C. M.; Pierotti, M. A. Absence of Fhit protein in primary lung tumors and cell lines with FHIT gene abnormalities. Cancer Res. 1997, 57, 5207-5212.
24. Petitjean, A.; Mathe, E.; Kato, S.; Ishioka, C.; Tavtigian, S. V.; Hainaut, P.; Olivier, M. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum. Mutat. 2007, 28, 622-629.
25. Campiglio, M.; Bianchi, F.; Andriani, F.; Sozzi, G.; Tagliabue, E.; Menard, S.; Roz, L. Diadenosines as FHIT-ness instructors. J. Cell Physiol. 2006, 208, 274-281.
26. Burke, L.; Khan, M. A.; Freedman, A. N.; Gemma, A.; Rusin, M.; Guinee, D. G.; Bennett, W. P.; Caporaso, N. E.; Fleming, M. V.; Travis, W. D.; Colby, T. V.; Trastek, V.; Pairolero, P. C.; Tazelaar, H. D.; Midthun, D. E.; Liotta, L. A.; Harris, C. C. Allelic deletion analysis of the FHIT gene predicts poor survival in non-small cell lung cancer. Cancer Res. 1998, 58, 2533-2536.
27. Mitsudomi, T.; Hamajima, N.; Ogawa, M.; Takahashi, T. Prognostic significance of p53 alterations in patients with non-small cell lung cancer: a meta-analysis. Clin. Cancer Res. 2000, 6, 4055-4063.
28. Steels, E.; Paesmans, M.; Berghmans, T.; Branle, F.; Lemaitre, F.; Mascaux, C.; Meert, A. P.; Vallot, F.; Lafitte, J. J.; Sculier, J. P. Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis. Eur. Respir. J. 2001, 18, 705-719.
29. Ahrendt, S. A.; Hu, Y.; Buta, M.; McDermott, M. P.; Benoit, N.; Yang, S. C.; Wu, L.; Sidransky, D. p53 mutations and survival in stage I non-small-cell lung cancer: results of a prospective study. J. Natl. Cancer Inst. 2003, 95, 961-970.
30. Nishizaki, M.; Sasaki, J.; Fang, B.; Atkinson, E. N.; Minna, J. D.; Roth, J. A.; Ji, L. Synergistic tumor suppression by coexpression of FHIT and p53 coincides with FHIT-mediated MDM2 inactivation and p53 stabilization in human non-small cell lung cancer cells. Cancer Res. 2004, 64, 5745-5752.
31. Dempke, W.; Voigt, W.; Grothey, A.; Hill, B. T.; Schmoll, H. J. Cisplatin resistance and oncogenes - a review. Anticancer Drugs 2000, 11, 225-236.
32. Nagel, S.; Califano, R.; Thatcher, N.; Blackhall, F. Gemcitabine and carboplatin in combination for the treatment of advanced, metastatic, non-small cell lung cancer. Expert Opin. Pharmacother. 2007, 8, 3265-3275.
33. Johnson, K. R.; Ringland, C.; Stokes, B. J.; Anthony, D. M.; Freemantle, N.; Irs, A.; Hill, S. R.; Ward, R. L. Response rate or time to progression as predictors of survival in trials of metastatic colorectal cancer or non-small-cell lung cancer: a meta-analysis. Lancet Oncol. 2006, 7, 741-746.